Company intelligence
ECRI
The Most Trusted Voice in Healthcare
About ECRI
ECRI is an independent, nonprofit organization with more than 50 years of experience improving the safety, quality, and cost-effectiveness of care across every healthcare setting. We are one of the most trusted names in healthcare safety — not because we say so, but because the evidence speaks for itself. ECRI is designated an Evidence-based Practice Center by the U.S. Agency for Healthcare Research and Quality. ECRI and the Institute for Safe Medication Practices PSO is federally certified by the U.S. Department of Health and Human Services. And ECRI operates the only independent medical device testing labs in North America, where biomedical engineers conduct hands-on safety and human factors usability testing free from manufacturer influence. Tens of thousands of members worldwide rely on ECRI's research, data, and guidance to reduce risk, make smarter purchasing decisions, and improve patient outcomes. Our solutions span clinical data analytics, market and competitive intelligence, health technology assessments, safety alerts, and device testing — giving health system leaders a single, unbiased source of truth in a complex and often conflicted marketplace. Our portfolio extends across the full scope of patient safety. The Institute for Safe Medication Practices, acquired by ECRI in 2020, is the nation's leading nonprofit dedicated to preventing medication errors. The Just Culture Company, acquired in 2024, partners with healthcare and other high-risk industries to build sustainable safety cultures and prevent harm before it occurs. Strict conflict-of-interest policies and an unwavering commitment to transparency have defined ECRI for five decades. We have no financial relationships with device manufacturers or vendors — which is precisely what makes our guidance worth trusting. For healthcare leaders who need answers they can act on with confidence, ECRI delivers the independent, evidence-based assurance that patient safety demands.
Verified activity
Signals from ECRI
3 published signals
Research & Knowledge
ECRI published the latest Emerging Health Care Innovation Brief (Vol. 4 | Issue 17) detailing the approval of Centanafadine as a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor for treating ADHD.
Reported by ECRI
People
ECRI appointed Professor Najmedin Meshkati, PhD, to its Board of Trustees
Reported by ECRI
People
ECRI welcomed a fellow UIC DrPH candidate named Renee Mulligan as the Director of the PSO and Consulting.
Reported by Jenn Trallo Schreiber, MSN, MBA, RN, CPPS, CPHQ, CPHFH, CPAFH